Pfizer Aktie

Pfizer für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 852009 / ISIN: US7170811035

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
30.04.2025 10:51:00

Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of safety concerns. Could Pfizer solve the issue by acquiring an up-and-coming biotech with a promising obesity drug in clinical development?The good news for Pfizer is that it shouldn't have any problems finding an acquisition candidate if it chooses to go that route. I can think of two great targets off the top of my head.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Pfizer Inc.mehr Analysen

29.04.25 Pfizer Buy Jefferies & Company Inc.
29.04.25 Pfizer Neutral JP Morgan Chase & Co.
29.04.25 Pfizer Neutral UBS AG
14.04.25 Pfizer Buy Jefferies & Company Inc.
14.04.25 Pfizer Neutral UBS AG
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Altimmune Inc Registered Shs 4,56 1,58% Altimmune Inc Registered Shs
Pfizer Inc. 21,37 1,67% Pfizer Inc.
Viking Holdings Ltd Registered Shs 40,93 -0,24% Viking Holdings Ltd Registered Shs
Viking Therapeutics Inc 25,04 7,31% Viking Therapeutics Inc